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Abstract
Background: The at-risk mental state (ARMS) describes individuals at high risk of developing schizophrenia or psychosis.
The use of antipsychotics in this population is not supported, because most individuals with ARMS are unlikely to
develop psychosis. Anti-inflammatory treatments and polyunsaturated fatty acids (PUFAs) may have some beneficial
effects in the treatment of ARMS. There have been no controlled clinical trials in which researchers have investigated
the use of minocycline for ARMS and no trials involving PUFAs in combination with other proposed treatments. There
is a need to find effective, tolerable and inexpensive interventions for individuals with ARMS that are available in high-,
low- and middle-income countries.
Methods/design: A 6-month intervention study of minocycline and/or omega-3 fatty acids added to treatment as usual
(TAU) in patients with ARMS will be conducted in Pakistan using a randomised, placebo-controlled, double-blind factorial
design. A total of 320 consenting patients with capacity will be recruited from the community, general practitioner clinics
and psychiatric units. Allowing for a 25% dropout rate, we will recruit 59 completing participants into each study arm, and
in total 236 will complete the study. We will determine whether the addition of minocycline and/or omega-3 fatty acids
to TAU attenuates the rate of transition from ARMS to first-episode psychosis and improves symptoms and/or
level of functioning in ARMS. We will also investigate whether any candidate risk factors, such as negative symptoms,
influence treatment response in the ARMS group. The primary efficacy endpoint is conversion to psychotic disorder at
12 months after study entry. Analysis will be done according to the intention to treat principle using analysis
of variance, chi-square tests and adjusted ORs to assess between-group differences. Cox regression analysis will be used
to evaluate potential between-group differences in time to onset of psychosis.
Discussion: The outcomes of this trial will provide evidence of the potential benefits of minocycline and PUFAs in the
treatment of ARMS. Both minocycline and PUFAs are inexpensive, are readily available in low-/middle-income countries
such as Pakistan, and if proven, may be safe and effective for treating individuals with ARMS.
Trial registration: ClinicalTrials.gov, NCT02569307. Registered on 3 October 2015.
Keywords: Minocycline, Omega-3 fatty acids, PUFA, At-risk mental state (ARMS), Ultra-high risk (UHR) schizophrenia, Global
mental health
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Background
The at-risk mental state (ARMS) describes individuals at
increased risk of developing psychosis. Operationalised
criteria have been developed to identify young persons
with ARMS [1]. Authors of a meta-analysis of 27 studies
with a combined sample of 2500 subjects reported a
transition to psychosis rate of 18% at 6 months, rising to
22% at 1 year [2]. These studies were undertaken in
Europe, the United States and Australia, and transition
rates are likely to be higher, approaching 40%, in
countries with less-established mental health care sys-
tems [3]. Individuals who experience symptoms of
ARMS are mostly help-seeking [4], making it a critical
period during which an intervention could be delivered
to prevent conversion to psychosis, improve symptoms
and reduce distress. Most of the disability develops
before the onset of frank psychosis [5], and earlier treat-
ment of psychosis is linked to better outcomes [6].
Interventions tested for ARMS include antipsychotics
[7] and cognitive behavioural therapy (CBT) [8]. The use
of antipsychotics in this population is not supported in,
for example, national clinical guidance [9], because a
large proportion of individuals with ARMS are unlikely
to develop psychosis. Furthermore, antipsychotics can
cause side effects such as weight gain and other meta-
bolic disturbances. An alternative approach is to explore
the effectiveness of interventions within a clinically
staged approach where the earlier in the course of illness
treatment is offered, the safer and more tolerable it
should be compared with treatments used later in the
illness, whilst remaining effective in terms of remission
and recovery rates [10].
There is persuasive evidence to test the use of minocy-
cline in individuals with ARMS. Authors of a meta-
analysis of minocycline augmentation of antipsychotics
pooled the results of four randomised controlled trials
including young adults in the early phase of schizophre-
nia [11] and found that minocycline was superior to pla-
cebo in reducing total scores on the Positive and
Negative Syndrome Scale (PANSS), the PANSS negative
subscale, and the PANSS general subscale. Minocycline
was equivalent to placebo for all-cause discontinuation
and for discontinuation because of adverse events. In
addition, minocycline has a well-established effectiveness
and safety profile in adolescents and young adults [12].
Authors of three systematic reviews [13–15] of inter-
ventions in the ARMS group found that antipsychotics,
CBT and omega-3 fatty acids may have some effect on
preventing or delaying the onset of psychosis, but all of
these authors noted the need for ongoing research. A
replication study of omega-3 fatty acids with a larger
sample would be especially important, given that this
treatment is relatively safe and has few health risks in a
drug-naïve population that could gain other potential
benefits (such as improving cardiovascular status). In a
subsequent study to determine whether omega-3 fatty
acids in combination with a high-quality psychosocial
intervention, cognitive behavioural case management
(CBCM), was more effective than placebo plus CBCM,
researchers did not detect a difference in transition to
psychosis at 6 months [16]. However, the lower-than-
expected transition rate may have prevented a test of the
main hypothesis, and the substantial symptomatic and
functional improvement in both groups with the other
treatments received (i.e., CBCM and antidepressants) is
likely to have produced a ceiling effect beyond which
omega-3 fatty acids, even if effective, could not be shown
to confer additional benefits. Neither CBT nor CBCM is
widely available in low- and middle-income countries,
unlike nutritional supplements and antibiotics.
In summary, there is a need to find effective, tolerable,
inexpensive and safe interventions for individuals with
ARMS, especially in view of the lack of availability of
high-quality psychosocial interventions in low-/middle-
income countries. Using a factorial design, we will com-
pare placebo with minocycline and omega-3 fatty acids
alone, as well as in combination, in the treatment of indi-
viduals with ARMS in Pakistan. The novel aspects of this
trial include that (1) minocycline has not been tested as a
treatment for individuals with ARMS, (2) minocycline and
omega-3 fatty acids have not previously been tested in
combination and potentially have additive/synergistic ef-
fects due to their modes of action, and (3) no drug trials
for ARMS have been undertaken in Pakistan or similar
low- and middle-income countries.
Methods/design
Objectives
The aim of the study is to evaluate the efficacy and toler-
ability of minocycline and omega-3 fatty acids in individ-
uals with ARMS and specifically to determine whether
the addition of minocycline and/or omega-3 fatty acids
to treatment as usual (TAU) in an operationalised
ARMS population in Pakistan (1) attenuates the rate or
incidence of transition from ARMS to first-episode
psychosis and (2) improves symptoms and/or level of
functioning of individuals with ARMS. In addition, we
will explore whether candidate risk factors, such as
negative symptoms, socio-demographic characteristics
and neurobiological variables, including metabolic
parameters (such as erythrocyte membrane fatty acids
and, where possible, cytokines), influence the transition
to psychosis in the ARMS group.
Study design
We are conducting a 6-month intervention study of
minocycline and/or omega-3 fatty acids added to TAU
in patients with ARMS, using a randomised, placebo-
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controlled, double-blind factorial design. In practice,
TAU in this population in Pakistan comprises no specific
treatment, whether psychological or pharmacological.
Participants will be randomly assigned to either (1)
placebo, (2) minocycline, (3) omega-3 fatty acids or (4)
minocycline and omega-3 fatty acids in combination.
Blinding will be maintained because participants will re-
ceive equivalent numbers of tablets. In a factorial design
the objective is generally not to compare arms with each
other; instead, combinations of experimental conditions
are compared. Each experimental condition in a factorial
design represents a different treatment protocol. It al-
lows a test of the possibility that the interventions being
tested have additive or multiplicative benefits.
Primary outcome measure
The primary efficacy endpoint will be transition to
psychotic disorder at 12 months after study entry.
Transition is operationally defined using the positive
symptom subscales in the Comprehensive Assessment
of At Risk Mental States (CAARMS) [17] as one of
the following:
 Unusual thought content held with delusional
intensity (global score 6) occurring several times or
more per week (frequency and duration score > 3)
 Non-bizarre ideas held with delusional conviction
(global score 6) occurring several times or more per
week (frequency and duration score > 3)
 Perceptual abnormalities in any modality (global
score ≥ 5) occurring several times or more per week
(frequency and duration score > 3)
 Disorganised speech (global score ≥ 5) occurring
several times or more per week (frequency and
duration score > 4)
Secondary outcome measures
Secondary outcome measures are as follows:
 Change in severity of ARMS symptoms between
entry (baseline) assessment and at 3, 6 and
12 months measured as difference in scores on the
CAARMS
 Change in social and occupational functioning
between baseline and 3, 6 and 12 months measured
using the Social and Occupational Functioning
Assessment Scale (SOFAS) [18]
 Change in cognitive scores between baseline and 3,
6 and 12 months measured using the CogState
battery [19]
 Adverse effects of medications: proportion
developing adverse effects as a function of severity
 Treatment with antipsychotic medication (from
participant self-report and subsequent confirmation
by clinician or by prescription evidence), because
this is likely to correlate with conversion to
psychosis
 Change in severity of depressive symptoms between
entry at baseline and at 3, 6 and 12 months
measured as the difference in scores on the
Montgomery-Åsberg Depression Rating Scale
(MADRS) [20]
Sample size
Sample size estimates are based on the expected transi-
tion rate to psychosis of 30%, and, on the basis of previ-
ous research, we expect to achieve a clinically
meaningful reduction to 15% [21, 22] following treat-
ment with minocycline and omega-3 fatty acids. With
80% power and at a 5% significance level, we will require
a sample size of 59 per treatment arm to detect the ex-
pected difference. We are allowing for a drop-out rate of
25%, and in order to maintain 59 completing partici-
pants per arm, we will recruit 80 participants to each of
the 4 trial arms. Therefore, we intend to recruit 320 par-
ticipants in total.
Study participants
Inclusion criteria
Participants should fulfil all of the following criteria:
 Male or female individuals aged 16–35 years
 Meet the criteria for ARMS using CAARMS
operationalised intake criteria based on three groups
(vulnerability, attenuated psychosis, or brief limited
intermittent psychotic symptoms group)
 Assessed as competent to provide informed consent
Exclusion criteria
Individuals meeting any of the following criteria will be
excluded:
 A history of psychotic illness (treated or untreated)
 IQ < 70 and/or a history of learning disability
 Any pre-existing inflammatory conditions (e.g.,
rheumatoid arthritis)
 Organic brain disease (e.g., epilepsy)
 Previous treatment with an antipsychotic or mood-
stabilising agent
 Prior history of intolerance or serious side effects
(hepatotoxicity, photosensitivity, blood dyscrasia) of
any of the tetracyclines or omega-3 fatty acids
 Concomitant penicillin therapy or concomitant
anticoagulant therapy
 Active substance abuse (except nicotine or caffeine)
or dependence within the last 3 months, according
to Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition, criteria
Qurashi et al. Trials  (2017) 18:524 Page 3 of 9
 Treatment with warfarin or lamotrigine
 Current or previous treatment with tetracycline
antibiotics or omega-3 fatty acids in the 3 months
before study entry
 Current treatment with any anti-inflammatory
medication
 Treatment with electroconvulsive therapy within the
12 weeks preceding the study
 Active expression of suicidal ideation or current
aggressive/dangerous behaviour
 Relevant current or past hematologic, hepatic, renal,
neurologic or other medical disorder that, in the
opinion of the principal investigator (PI), might
interfere with the study
 Pregnant or breastfeeding
Withdrawal criteria
Participants may be withdrawn from the research study
for the following reasons:
 At their own request
 At the discretion of the investigator
 Participants who meet the exit criteria for transition
to psychosis or develop mania
 Experiencing a serious adverse event or moderate to
severe adverse drug reaction
 Participants meeting criteria for insufficient
adherence, defined as either taking < 75% of trial
medication between assessment points at baseline, 1,
3 and 6 months or missing trial medications
altogether for ≥ 7 days in any period
 Becoming pregnant
 An antipsychotic being prescribed during the course
of the study
Recruitment procedures
Consenting patients with capacity will be recruited
from the community, general practitioner clinics and
psychiatric units in Pakistan.
Instruments
The following instruments will be used:
 Prodromal Questionnaire-16 (PQ-16) [23]: A brief
self-report screening questionnaire that assesses the
presence of attenuated psychotic symptoms, the PQ-
16 is a reliable measure and correlates well with the
CAARMS. It is a good screening instrument, and
the low number of items makes it feasible to screen
populations [24].
 SOFAS [18]: A global rating of current functioning,
this instrument focuses on social and occupational
functioning that is independent of the overall
severity of the individual’s psychological symptoms
[25].
 CAARMS [17]: A semi-structured interview for the
identification of individuals at increased risk of de-
veloping a first-episode psychotic disorder, it shows
good to excellent concurrent, discriminant and pre-
dictive validity and excellent inter-rater reliability
[17].
 CogState [19]: This instrument comprises a number
of individual tasks, each designed to test a specific
area of cognition. The test battery is culturally
neutral and user-friendly, and it covers all necessary
cognitive domains. It comprises a range of compu-
terised cognitive tasks able to measure baseline and
change in all cognitive domains, and it shows good
reliability and validity [26].
 MADRS [20]: MADRS is an index of depression
administered by a trained clinician who assigns a
severity rating for symptoms of depression on the
basis of a personal interview. The scale has
demonstrated strong reliability, validity and
sensitivity to change [27].
 Schizotypal Personality Questionnaire [26]: A self-
report measure of schizotypal personality disorder,
this questionnaire incorporates nine schizotypal
features. The scale consists of 74 yes/no items and has
been shown to have strong reliability and validity [28].
We will use a structured rating scale to capture
information on side effects. All the instruments have
been translated into the Urdu language.
Study procedure
The schedule of visits and study procedures is outlined
in Fig. 1 and in the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
diagram (Fig. 2) and a completed SPIRIT checklist is
given in Additional file 1.
Consent visit
A trained research assistant (RA) will visit potential par-
ticipants at their homes or places convenient to them
and confirm their suitability for inclusion by screening
them using the inclusion/exclusion criteria, confirming
consent, and pregnancy testing, if appropriate. The RA
will arrange for a doctor to complete checklists for
medical history, physical examination and haemato-
logical investigations. Participants will also complete the
MADRS. Random assignment to the treatment arms will
be stratified using the MADRS (total score cut-off ≥ 21)
because depressive symptoms may affect illness progres-
sion. A computer-generated random sequence based on
a block randomised design (with varying block sizes of 2,
4, 6 and 8 in order to reduce predictability [29]) will be
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administered by an independent third party until all
study data are collected and verified. Participants, par-
ents and those involved in administering interventions,
assessing outcomes, data entry and/or data analysis will
be blind to group assignments. All eligible participants
will be randomised to one of the four study arms and al-
located a unique identification number, and they will
commence study drug treatment within 1 week of
providing consent.
Baseline visit
The baseline clinical and neuropsychological measures
will be completed. The participants will be given a 1-
week supply of the study medication appropriate to
the trial arm to which they have been randomised; a
study information sheet explaining that they are in a
clinical study; and the telephone numbers of the se-
nior research clinicians and the clinical trial office, as
well as the name of the local PI. In accordance with
International Conference for Harmonisation good
clinical practice guidelines, copies of all the above will
be placed in the individuals’ records along with con-
tact names and telephone numbers.
Follow-up visits
The first follow-up visit will occur after 1 week of treat-
ment with the trial medication to check for safety and
tolerability of the treatment initiated. At the first follow-
up visit, the participant will also receive sufficient trial
medication for the rest of the month. Follow-up visits
will be conducted at 1-month intervals for the 6-month
duration of the intervention and at a final visit 6 months
Fig. 1 Study flowchart outlining the timetable of study procedures. CAARMS Comprehensive Assessment of At Risk Mental States, MADRS
Montgomery-Åsberg Depression Rating Scale, PQ-16 Prodromal Questionnaire-16, SOFAS Social and Occupational Functioning Assessment Scale,
SPQ Schizotypal Personality Questionnaire
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after the end of the intervention (12 months after base-
line). During the monthly visits, along with clinical and
safety assessments, the participants will complete the
MADRS, CAARMS and SOFAS assessments, and they
will also receive their study medication. The RA will col-
lect and deliver these to the participant. This will give
the research team the opportunity to closely monitor the
participant’s physical and mental health, side effects and
adherence (by pill count). Female participants with
childbearing capacity taking part in the clinical trial will
take a pregnancy test regularly. If they should become
pregnant during the study, they will be withdrawn from
the study.
Final visit
At this visit all clinical, neuropsychological and physical
assessments will be completed. At all visits the partici-
pants’ cumulative clinical drug treatment will be updated
from case notes.
Data management
Data will be collected by trained RAs to maintain data
confidentiality and anonymisation. A unique trial iden-
tity number will be used for participant data collection
and processing. Trial documents (consent form, source
documents, assessment tools, case report forms) in hard
copies will be kept at the study site in locked file
cabinets. Electronic data will be encrypted and
password-protected. Backup electronic data will be saved
at two places on a hard drive and an institution server.
Access to data, both in hard copies and in electronic
versions, will be restricted, and only designated persons
as approved by the site PI will handle the data. A signed
duty log will be used every time the data is accessed.
After trial completion the PI will be responsible for data
archiving and preservation. Any application for data
sharing will also be handled by PI, and access to data
will be granted with PI permission.
Intervention
Minocycline
Minocycline will be administered orally for a 6-month
period. We have chosen to trial 200 mg because this is
the dose used in previous trials in early-phase schizo-
phrenia [30, 31]. A titration schedule will be used to
minimise attrition. During the first week of the study,
participants will receive a 100-mg capsule of minocy-
cline (or matching placebo) daily. If this is tolerated, the
Fig. 2 Schedule of enrolment, interventions and assessments. CAARMS Comprehensive Assessment of At Risk Mental States, MADRS Montgomery-
Åsberg Depression Rating Scale, PQ-16 Prodromal Questionnaire-16, SOFAS Social and Occupational Functioning Assessment Scale
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participants will receive 200 mg of minocycline (or
matching placebo) for the remaining intervention period.
If a participant complains of side effects, the treating
psychiatrist (blind to the intervention) will be allowed to
omit up to the next two doses of medication and con-
tinue from the last prescribed dose. If, despite this, the
participant is unable to tolerate an increased dose, the
dose will be reduced by 50-mg decrements to a tolerable
dose of minocycline or matching placebo.
Omega-3 fatty acids
Omega-3 fatty acids will be administered orally, and the
daily dose of 1.2 g/day is based on trials in an ultra-high
risk population [32]. The active treatment will comprise
600-mg capsules containing concentrated marine fish
oil. The proposed daily dose of two capsules will provide
720 mg of eicosapentaenoic acid and 480 mg of
docosahexaenoic acid.
Placebo
Placebo capsules will be manufactured carefully to re-
semble the study drugs in appearance. The omega-3
fatty acid (in a soft-shell capsule) and minocycline (in a
hard-shell capsule) will appear different because of their
individual casing, but all participants will take one hard-
shell and two soft-shell capsules, with placebo replacing
the active comparator as required.
Research assistant training and inter-rater reliability
RAs in Pakistan are trained in the assessment measures,
and inter-rater reliability will be measured throughout
the study by local PIs.
Statistical analysis
Initially the data will be described using summary statis-
tics, and possible between-group differences will be
assessed using analysis of variance (ANOVA) and chi-
square tests. Analysis in all cases will be by intention to
treat. All protocol violations and major deviations will
be recorded as they occur and will be included in re-
ports on trial findings. Because the primary outcome is
categorical, logistic regression will be used to assess
between-group differences, which will be described using
ORs and corresponding 95% CIs. If between-group dif-
ferences in demographic or other factors are observed,
we will estimate adjusted ORs. Secondary and subgroup
analyses will also use ANOVA and logistic regression
along with other standard hypothesis-testing methods,
including Cox regression to analyse potential between-
group differences in time to onset of psychosis with
non-completers and those who do not develop psychosis
included as censored observations. A complete statistical
analysis plan will be written prior to database lock and
subsequently will be discussed and approved by the trial
steering committee.
Discontinuation
The trial will end either when the study period ends or
by the recommendation of the drug safety monitoring
board if serious untoward events occur. For individual
study participants, the intervention will be discontinued
if there are adverse effects that warrant this or if the par-
ticipant requests to exit the study.
Adverse event reporting
Adverse events, whether related to study conduct and
intervention or not, will be recorded. If there is a serious
adverse event, immediate notification of collaborating
investigators and sites will be undertaken by the site PI.
All essential and appropriate measures will be taken to
ensure patient safety. If there are safety issues with the
investigational medicines, immediate action will be taken
across the whole study to prevent others from avoidable
harm.
Discussion
In Pakistan and other low-/middle-income countries,
there is no specific TAU for individuals with ARMS.
Minocycline and omega-3 fatty acids are inexpensive
and widely available, and evidence suggests that they
may be effective in delaying or preventing the onset of
full psychosis. The compounds may be feasible and
beneficial interventions for patients with ARMS, but
there is a strong need to assess evidence of their efficacy.
Should minocycline and/or omega-3 fatty acids prove to
be effective, this will contribute to the growing body of
evidence for treatment options in ARMS.
Trial status
This clinical trial was registered in October 2015
(ClinicalTrials.gov, NCT02569307), and participants are
being recruited until the end of 2017.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 49 kb)
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